AI-enabled analysis and multimodal imaging boost ROI by accelerating validation, lowering drug-development attrition, reducing animal cohorts and improving data precision.Dublin, Oct. (GLOBE NEWSWIRE) ...
Engitix has appointed Ryan Richardson as an Independent Non-Executive Director as the biotechnology company advances its ...
Strategic partnerships, splicing modulators and non-coding RNA targets offer high-potential routes into oncology, rare disease and CNS therapiesDublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- "RNA Targeting ...
Curi Bio Expands the Curiverse™ with New Disease Models, Casting Kits, and Application-Ready Solutions ...
Overview: Fraud detection, radiology, and retention analytics carry the strongest proof.Vendor claims shrink in neutral tests ...
Hold: $1.2bn Zealand obesity deal, GB-0895 Phase 3 asthma readout vs Tezspire, cash burn risks, AI platform optionality—read ...
SAN DIEGO, CA / ACCESS Newswire / October 14, 2026 / Ablexis, LLC, a biopharmaceutical company focused on advancing human antibody drug discovery through provision ...
Engitix Ltd., a biotechnology company pioneering extracellular matrix (ECM)-based drug discovery and development in oncology, fibrosis and fibro-inflammatory diseases, today announced the appointment ...
Partnership applies Deep Origin's virtual screening architecture to BioAge's targets, identified from human data, to ...
Tech Times on MSN
Plain-English AI produces validated drug-candidate proteins against rare disease target
AI protein design leapt forward: University of Washington researchers built Prompteina, the first model generating 3D protein ...
Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results